SCHEMBL9907696

SCHEMBL9907696

O=C(O)c1ccc2c(F)cnc(-c3ccc(Cl)cc3Cl)c2c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 10/20 0.59
SRD5A2 P31213 2/20 0.46
MRGPRX4 Q96LA9 1/20 0.45
KDM4C Q9H3R0 1/20 0.42
SRD5A1 P18405 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
CRHBP P24387 1/20 0.41
RAB9A P51151 1/20 0.41
CRHR2 Q13324 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CNR1 P21554 2/20 0.40
MAPT P10636 1/20 0.40
MAP2K4 P45985 1/20 0.40
KMO O15229 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907521 0.91 HTR5A (0.52) HTR5ASRD5A2MRGPRX4SRD5A1MAPT
SCHEMBL9907542 0.90 HTR5A (0.72) HTR5AKDM4CMAP2K4
SCHEMBL9908004 0.90 HTR5A (0.51) HTR5ASRD5A2MRGPRX4SRD5A1MAPT
SCHEMBL9907732 0.88 SRD5A2 (0.49) HTR5ASRD5A2KDM4CSRD5A1KDM4E
SCHEMBL9907763 0.88 HTR5A (0.49) HTR5ASRD5A2MRGPRX4KDM4CSRD5A1
SCHEMBL9907640 0.86 HTR5A (0.71) HTR5ACNR1
SCHEMBL9907692 0.86 HTR5A (0.55) HTR5ACNR1MAPTMAP2K4
SCHEMBL9907718 0.85 HTR5A (0.59) HTR5ASRD5A2MRGPRX4KDM4CSRD5A1
SCHEMBL9908007 0.85 HTR5A (0.54) HTR5ASRD5A2MRGPRX4KDM4ERAB9A
SCHEMBL9909285 0.85 SCN9A (0.51) HTR5AMRGPRX4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885SRD5A2 509/4885MRGPRX4 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.